0R34 Stock Chart & Stats
$234.83
-$3.20(-2.19%)
At close: 4:00 PM EST
$234.83
-$3.20(-2.19%)
Day’s Range― - ―
52-Week Range$154.82 - $269.50
Previous CloseN/A
Volume15.31K
Average Volume (3M)13.77K
Market Cap
$618.61B
Enterprise Value$597.07B
Total Cash (Recent Filing)$22.05B
Total Debt (Recent Filing)$54.99B
Price to Earnings (P/E)29.7
Beta0.60
Next Earnings
Jul 15, 2026EPS Estimate
2.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.67
Shares Outstanding2,407,217,000
10 Day Avg. Volume10,604
30 Day Avg. Volume13,774
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)6.18
Price to Sales (P/S)5.35
P/FCF Ratio25.59
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue6.20
Enterprise Value/Gross Profit8.96
Enterprise Value/Ebitda17.83
Forecast
1Y Price Target
$273.21Price Target Upside16.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)11.59
Revenue Forecast (FY)$101.04B
Bulls Say, Bears Say
Bulls Say
Durable Revenue Growth & High MarginsJohnson & Johnson's multi-year top-line expansion and persistently high gross and operating margins indicate durable core profitability. High margins across segments provide structural capacity for R&D, launches and reinvestment, supporting multi-quarter growth even with episodic earnings normalization.
Strong Absolute Cash Generation & Payout TrackLarge absolute free cash flow and a sizable cash balance provide durable financial flexibility for R&D, capex and shareholder returns. A 64‑year dividend growth streak and reiterated ~ $21B FCF target reflect disciplined capital allocation and an ability to support investment and payouts over the medium term.
Diversified High-growth Product Portfolio & LaunchesA broad set of growing franchises and multiple new approvals reduce single-product dependency and create multi-year revenue runway. Consistent launch traction across oncology, immunology and MedTech increases resilience to competitive shocks and supports structural growth as older assets decline.
Bears Say
Severe STELARA Sales ErosionThe sharp STELARA decline from biosimilars/novel classes is a structural revenue loss that materially pressures near‑term growth and forces heavier reliance on newer launches. Replacing a blockbuster biologic takes multiple years, raising execution risk and portfolio gap exposure.
Margin Deleverage From Launches And MixSustained heavy launch and SG&A investment combined with adverse mix and tariffs is compressing operating margins. If launch spending persists to capture market share, operating leverage may remain below historical peaks, limiting incremental free cash flow and profitability over coming quarters.
Weaker Free Cash Flow Momentum & ConversionA decline in FCF and lower OCF-to-net-income conversion suggests working‑capital or timing volatility that reduces predictability of cash available for buybacks, M&A and capex. Achieving the full‑year ~$21B FCF target requires execution; missed momentum would strain capital flexibility.
Johnson & Johnson News
0R34 FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest share price was $154.82 and its highest was $269.50 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $618.61B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jul 15, 2026 which is tomorrow.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Apr 14, 2026. The company reported $2.7 earnings per share for the quarter, beating the consensus estimate of $2.677 by $0.023.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson does not currently pay dividends.
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.86.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,407,217,000 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.7 in its last earnings report, beating expectations of $2.677. Following the earnings report the stock price went up 2.217%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in GB:0R34
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$273.21 (16.35% Upside)
$273.21 (16.35% Upside)
Blogger Sentiment
Bullish
GB:0R34 Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.08%
12-Months-Change
Fundamentals
Return on Equity
26.26%
Trailing 12-Months
Asset Growth
3.73%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
0R34 Sales Breakdown
64.12% Innovative Medicine
35.88% MedTech
0R34 Stock 12 Month Forecast
Average Price Target
$273.21
▲(16.35% Upside)
Technical Analysis
Options Prices
Currently, No data available
---